Panorama^TM NIPT performed by Natera International Inc., USA. Panorama is a market-leading non-invasive prenatal screening test (NIPT) that reveals your baby’s risk for genetic disorders as early as nine weeks. Panorama analyzes the baby’s (placental) DNA through a simple blood draw from the mother’s arm. Panorama can now perform the test for twin pregnancies.
https://www.natera.com/panorama-test

Horizon^TM test looks at your genes to see if you’re a carrier for up to 274 autosomal-recessive and X-linked genetic conditions. Carriers usually do not have any symptoms. Since most individuals do not know if they have a gene for a disorder, they can pass the gene to their children. If both parents are carriers of the same recessive gene for a condition, there is a 50% chance that the children are the same as the carrier parents and a 25% chance that the children will get the gene from each parent and have the disorder. You can find a comprehensive list of the genes tested at:
https://www.natera.com/horizon-carrier-screen/what-it-screens

Vistara^TM is the most comprehensive prenatal single-gene screening test for serious genetic conditions that affect quality of life and that could benefit from early intervention. It identifies probability for 25 conditions that may have otherwise gone undetected until after birth or into childhood. All conditions are inherited in an autosomal or X-linked dominant fashion, which means that if the mutation is present, the child will be affected by the condition and experience related symptoms. Most results will be returned to your clinician within 2-3 weeks. Conditions screened by Vistara have a combined incidence of 1 in 600 – higher than that of Down syndrome for pregnancies in women under 32.

Conditions and more information can be found here:
https://www.natera.com/wp-content/uploads/2020/11/Womens-Health-Patient-Vistara-non-invasive-prenatal-screen.pdf
https://www.natera.com/womens-health/vistara-nipt-single-gene-test/

Reproductive medicine tests, both routine and esoteric, are offered. For some esoteric tests* PathLab has made arrangements with specialized testing laboratories in the USA to provide a complete range of tests. These include:

Cancer marker blood tests are of most use in determining the effectiveness of cancer treatment and detecting recurrent cancer. They are often used in health screens in asymptomatic individuals for earlier detection. However, cancer markers in the blood are not specific, nor are they diagnostic alone, and doctors must interpret them with other tests and clinical history. Examples of tests available are:

The FIT (Fecal Immunoassay Test) is a quantitative automated high-sensitive test for “hidden blood” in stool, an early indicator of colon cancer in asymptomatic individuals. The FIT test picks up minute amounts of blood that cannot be seen with the naked eye. It has proven to be an effective screening tool for detecting several gastrointestinal disorders such as colitis, polyps, early-stage cancers, and advanced adenomas. FIT collected on two days is an alternative cancer detection test if colonoscopy is not a screening option.